Relypsa Inc·4

Sep 2, 12:37 PM ET

Relypsa Inc 4

4 · Relypsa Inc · Filed Sep 2, 2016

Insider Transaction Report

Form 4
Period: 2016-09-01
Transactions
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2016-09-018720 total
    Exercise: $4.65Exp: 2021-06-08Common Stock (872 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2016-09-014,5000 total
    Exercise: $35.79Exp: 2025-06-03Common Stock (4,500 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2016-09-014,5000 total
    Exercise: $17.00Exp: 2026-06-20Common Stock (4,500 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2016-09-011,7440 total
    Exercise: $4.65Exp: 2021-03-30Common Stock (1,744 underlying)
  • Disposition to Issuer

    Common Stock

    2016-09-01$32.00/sh2,250$72,0000 total
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2016-09-016,9760 total
    Exercise: $4.65Exp: 2020-09-28Common Stock (6,976 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2016-09-0110,1400 total
    Exercise: $7.40Exp: 2023-07-23Common Stock (10,140 underlying)
  • Disposition from Tender

    Common Stock

    2016-09-01$32.00/sh33,962$1,086,7842,250 total
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2016-09-015810 total
    Exercise: $4.65Exp: 2020-11-29Common Stock (581 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2016-09-0115,6970 total
    Exercise: $3.96Exp: 2021-09-13Common Stock (15,697 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2016-09-019,0110 total
    Exercise: $3.96Exp: 2022-09-27Common Stock (9,011 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2016-09-013,8280 total
    Exercise: $23.96Exp: 2024-06-18Common Stock (3,828 underlying)
Footnotes (3)
  • [F1]Pursuant to the terms of the Agreement and Plan of Merger, dated as of July 20, 2016 (the "Merger Agreement"), by and among the Issuer, Galencia AG, a public limited company existing under the laws of Switzerland ("Parent"), and Vifor Pharma USA Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent, on September 1, 2016, shares disposed of in exchange for cash consideration of $32.00 per share, without interest, subject to any applicable withholding taxes.
  • [F2]Pursuant to the terms of the Merger Agreement, on September 1, 2016, each award of restricted stock units and stock options was cancelled in exchange for the right to receive $32.00 per share in cash less any applicable withholding taxes and in the case of stock options, less the applicable exercise price.
  • [F3]Pursuant to the terms of the Merger Agreement, on September 1, 2016, the stock option was cancelled and no cash payment was made as the exercise price exceeded $32.00 per share.

Documents

1 file
  • 4
    doc1.xmlPrimary

    FORM 4